Eledon Pharmaceuticals, Inc. Common Stock
$2.65
-$0.02 (-0.75%)
$2.62Day Range$2.79
Key Statistics
Market Cap
$216.97M
Shares Outstanding
81.3M
Primary Exchange
XNAS
Currency
USD
Type
CS
IPO Date
Sep 17, 2014
Round Lot
100
Locale
US
Trading Data
Day Open
$2.73
Day High
$2.79
Day Low
$2.62
Volume
558.4K
VWAP
$2.65
Prev Close
$2.67
Transactions
--
Acc. Volume
--
About Eledon Pharmaceuticals, Inc. Common Stock
Eledon Pharmaceuticals Inc is a clinical stage biotechnology company using immunology expertise in targeting the CD40 Ligand pathway to develop therapies to protect transplanted organs and prevent rejection, and to treat amyotrophic lateral sclerosis. Its compound in development is tegoprubart, an IgG1, anti-CD40L antibody with high affinity for the CD40L, a well-validated biological target that has broad therapeutic potential. It operates as one reportable segment, focused on the development of tegoprubart, to develop therapies to protect transplanted organs and prevent rejection, and to treat ALS.
PHARMACEUTICAL PREPARATIONSSIC 283433 employees19800 MACARTHUR BLVD., IRVINE, CA, 92612949-238-8090IPO Sep 17, 2014US / STOCKSActiveWebsite
Identifiers
- CIK
- 0001404281
- Composite FIGI
- BBG00241S542
- Share Class FIGI
- BBG00241S579
- Ticker Root
- ELDN
- SIC Code
- 2834
About Eledon Pharmaceuticals, Inc. Common Stock (ELDN) Stock
Eledon Pharmaceuticals, Inc. Common Stock (ELDN) closed the 2026-09-17 session at $2.65, down 0.75% versus the previous close (-0.02). The stock opened at $2.73 and traded between $2.62 and $2.79 during that session. Session trading volume was 558K shares. The volume-weighted average price (VWAP) is $2.65.
Eledon Pharmaceuticals Inc is a clinical stage biotechnology company using immunology expertise in targeting the CD40 Ligand pathway to develop therapies to protect transplanted organs and prevent rejection, and to treat amyotrophic lateral sclerosis. Its compound in development is tegoprubart, an IgG1, anti-CD40L antibody with high affinity for the CD40L, a well-validated biological target that has broad therapeutic potential. It operates as one reportable segment, focused on the development of tegoprubart, to develop therapies to protect transplanted organs and prevent rejection, and to treat ALS.
Eledon Pharmaceuticals, Inc. Common Stock has a market capitalization of $217.0 million. The company operates in the PHARMACEUTICAL PREPARATIONS industry classification. ELDN is listed on the XNAS exchange. The company employs approximately 33 people. Eledon Pharmaceuticals, Inc. Common Stock is headquartered in IRVINE, CA. The recorded listing date is 2014-09-17.
On this page you can find market ELDN stock price data, interactive price charts with multiple timeframes (1 day to max history), company financials including income statements, balance sheets, and cash flow statements, technical indicators (SMA 50, SMA 200, EMA 20, MACD, RSI), latest news and sentiment analysis, dividend history, stock splits, short interest data, float information, and related stocks.
Explore more: View today's market movers, use the stock screener, or browse all sectors. See more stocks in the PHARMACEUTICAL PREPARATIONS sector.